Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01844947
Recruitment Status : Completed
First Posted : May 3, 2013
Last Update Posted : August 9, 2018
Pierre Fabre Laboratories
Nordic Urothelial Cancer Oncology Group
Information provided by (Responsible Party):
Dr Anders Ullén, Karolinska University Hospital

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 18, 2017
  Actual Study Completion Date : June 5, 2018